We are live on ! Find out more
KCM

Kynam Capital Management Portfolio holdings

AUM $1.62B
1-Year Est. Return 138.67%
This Fund
S&P 500
This Quarter Est. Return
-21.69%
1 Year Est. Return
+138.67%
3 Year Est. Return
+268.43%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.19B
AUM Growth
-$502M
Cap. Flow
-$120M
Cap. Flow %
-10.12%
Top 10 Hldgs %
72.7%
Holding
36
New
6
Increased
14
Reduced
4
Closed
4

Top Buys

Rank Stock Value
1
PCVX icon
Vaxcyte
PCVX
+$69M
2
CLDX icon
Celldex Therapeutics
CLDX
+$32.1M
3
VERA icon
Vera Therapeutics
VERA
+$30.3M
4
TYRA icon
Tyra Biosciences
TYRA
+$24.3M
5
VRDN icon
Viridian Therapeutics
VRDN
+$23.4M

Top Sells

Rank Stock Value
1
NTRA icon
Natera
NTRA
+$137M
2
DVAX
Dynavax Technologies
DVAX
+$52.1M
3
LQDA icon
Liquidia Corp
LQDA
+$23.8M
4
TSVT
2seventy bio
TSVT
+$17.5M
5
PTGX icon
Protagonist Therapeutics
PTGX
+$15.1M

Sector Composition

Rank Sector Weight
1 Healthcare 98.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BNR
26
Burning Rock Biotech
BNR
$94.4M
$4.38M 0.37%
994,883
– –
STRO icon
27
Sutro Biopharma
STRO
$379M
$3.54M 0.3%
544,145
+180,000
+49% +$2.83M
DSGN icon
28
Design Therapeutics
DSGN
$736M
$3.49M 0.29%
+904,017
New +$4.31M
CRBU icon
29
Caribou Biosciences
CRBU
$156M
$2.99M 0.25%
3,269,147
+863,000
+36% +$1.12M
PRQR icon
30
ProQR Therapeutics
PRQR
$243M
$2.33M 0.2%
1,750,000
– –
CLYM
31
Climb Bio
CLYM
$735M
$1.28M 0.11%
1,047,000
+500,000
+91% +$811K
URGN icon
32
UroGen Pharma
URGN
$2B
$277K 0.02%
+25,000
New +$267K
PTGX icon
33
Protagonist Therapeutics
PTGX
$8.75B
– –
-390,792
Closed -$15.1M
SLRN
34
DELISTED
ACELYRIN
SLRN
– –
-847,366
Closed -$2.66M
SPY icon
35
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$781B
– –
-300,000
Closed -$176M
TSVT
36
DELISTED
2seventy bio
TSVT
– –
-5,953,825
Closed -$17.5M
1
2

Similar funds

IPW
Invictus Private Wealth Denver, Colorado $1.62B AUM 22.63% 1-Year Est. Return
WIC
Woodmont Investment Counsel Nashville, Tennessee $1.62B AUM 18.92% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return
TLFA
True Link Financial Advisors San Francisco, California $1.62B AUM 8.33% 1-Year Est. Return
KCM
Kathmere Capital Management Wayne, Pennsylvania $1.62B AUM 17.7% 1-Year Est. Return
PRA
Pine Ridge Advisers New York $1.62B AUM 16.97% 1-Year Est. Return
BW
Browning West Los Angeles, California $1.62B AUM 22.28% 1-Year Est. Return
CC
Covalis Capital London, United Kingdom $1.63B AUM 27.84% 1-Year Est. Return

Kynam Capital Management's Q1 2025 Portfolio in Review

As of Q1 2025, Kynam Capital Management held 36 positions worth $1.19B, down 30% from $1.69B the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Kynam Capital Management withdrew a net $120M in Q1 2025, closing 4 positions and reducing 4 holdings. Its most notable exit was 2seventy bio, an estimated $17.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 90% a quarter earlier.

Against the trend, Kynam Capital Management opened a new position in Legend Biotech worth $20.7M.

  • Kynam Capital Management's largest Q1 2025 buy was Legend Biotech: 610,000 shares worth $20.7M.
  • Kynam Capital Management added most to Vaxcyte in Q1 2025, an estimated $69M increase.
  • Kynam Capital Management's biggest Q1 2025 reduction was Natera, cutting an estimated $137M.
  • Kynam Capital Management fully exited 2seventy bio in Q1 2025, selling an estimated $17.5M.
  • Kynam Capital Management's ten largest holdings make up 73% of its $1.19B portfolio in Q1 2025.
  • Kynam Capital Management opened 6 new positions and closed 4 in Q1 2025.
  • Kynam Capital Management's portfolio value fell 30% quarter-over-quarter to $1.19B.

Based on Kynam Capital Management's 13F filing for Q1 2025, filed 15 May 2025.